![]() | |
Names | |
---|---|
Preferred IUPAC name
N-{[(2S)-1-Ethylpyrrolidin-2-yl]methyl}-2-hydroxy-3-iodo-6-methoxybenzamide | |
Other names
IBZM; Iolopride | |
Identifiers | |
![]() ![]() | |
3D model (JSmol) |
|
ChemSpider | |
PubChem CID |
|
UNII |
![]() ![]() |
CompTox Dashboard (EPA) |
|
| |
| |
Properties | |
C15H21IN2O3 | |
Molar mass | 404.248 g·mol−1 |
Pharmacology | |
V09AB02 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Iodobenzamide (IBZMoriolopride) is a pharmaceutical drug used for diagnostic purposes. It is a dopamine antagonist and it can be used by nuclear medicine physicians as a radioactive tracer for SPECT where the radioactive isotopeisiodine-123oriodine-125.[1][2] The main purpose of a brain study with IBZM is the differentiation of Parkinson's disease from other neurodegenerative diseases such as Lewy Body dementia and multiple system atrophy.
{{cite journal}}
: CS1 maint: multiple names: authors list (link)
![]() | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
![]() | This nuclear medicine article is a stub. You can help Wikipedia by expanding it. |